Novo Nordisk A/s

This study tests a new medicine called NNC4005-0001 to see if it is safe and tolerable for people with extra body weight and too much fat in the liver. About 60 adults will get either the medicine or a placebo (a dummy pill) just once. The study lasts about 7 to 8 months and focu…

This study tests a new medicine called CagriSema for weight loss in 2500 adults with obesity, some of whom also have type 2 diabetes. Participants will receive either CagriSema or the existing drug semaglutide to see which works better and is safer. The trial lasts about 83 weeks…

This study looks at how well oral semaglutide works for controlling blood sugar and weight in adults with type 2 diabetes. About 470 people in Hungary will take the pill as prescribed by their doctor and be followed for 5 to 7 months. Researchers will measure changes in blood sug…

This study looks at how three medicines—CagriSema, semaglutide, and cagrilintide—affect muscle health in 100 adults aged 50-70 with obesity and slightly high blood sugar. Participants will receive one of the drugs or a placebo for up to 15 months. The goal is to understand how th…

This study tests a new weekly injection (NNC0487-0111) for people who are overweight or have obesity and also have moderate-to-severe obstructive sleep apnea treated with a breathing machine. About 300 adults will receive either the study drug or a placebo to see if it helps redu…

This study tests whether a monthly injection called ziltivekimab can reduce heart failure-related deaths, hospitalizations, and urgent visits in people with heart failure and signs of inflammation. About 5,600 participants will receive either the drug or a placebo for up to 4 yea…

This study looks at the long-term safety and effectiveness of etavopivat, an experimental pill for sickle cell disease and thalassemia. About 480 adults, teens, and children who already benefited from etavopivat in a previous study will take the drug for up to 5 years. The goal i…

This early-stage study tests whether a new experimental medicine, NNC1679-0001, is safe and well-tolerated in healthy adults and people with type 2 diabetes. Participants receive a single injection of either the study drug or a placebo. The goal is to check for side effects and h…

This study tests a new once-weekly injection, NNC0487-0111, for weight loss in 1150 adults with obesity. Participants receive either the drug or a placebo. The main goal is to see how much body weight they lose over time.

This study tests a new once-weekly injection called NNC0662-0419 for people with type 2 diabetes. About 270 adults will receive either the new drug, an approved drug (semaglutide), or a placebo to see how well it controls blood sugar and affects weight. The goal is to find the be…

This study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who do not use a breathing machine. The goal is to see if the drug helps with weight loss and reduces sleep apnea events. Participa…

This study tests a new medicine called ziltivekimab in 10,000 people who recently had a heart attack. The goal is to see if a monthly injection can lower the risk of another heart attack, stroke, or death from heart disease. Participants are randomly assigned to receive either th…

This study tests whether a new medicine called ziltivekimab can reduce fatty plaque buildup in heart arteries after a heart attack. About 332 adults who recently had a heart attack will receive either the drug or a placebo for 15 months. The goal is to see if the drug helps contr…

This study tests a new medicine called CDR132L to see if it can improve heart structure and function in people with heart failure. About 200 adults aged 40-84 with stable heart failure will receive either CDR132L or a placebo by chance. The study lasts about 60 weeks and measures…

This study tests if a new insulin that is injected just once a week works as well as daily insulin shots to control blood sugar in people with type 2 diabetes. About 586 adults who have never used insulin before will take either the weekly insulin or a standard daily insulin for …

This study tests a potential new medicine called CDR132L in 200 people with heart failure. The goal is to see if it can improve heart structure and function. Participants will receive either the study drug or a placebo by chance, and the study lasts about 60 weeks.

This study follows 630 people with type 1 diabetes in Japan who are already prescribed Awiqli, a once-weekly insulin. Researchers will track side effects and blood sugar control over one year. The goal is to see how well the drug works in everyday medical practice.

This study tests a new oral medicine called Inno8 in 30 adults with hemophilia A, a bleeding disorder. The main goal is to see if different doses are safe and how the body handles the medicine. Participants will take multiple doses over about 11 weeks, and researchers will monito…

This early-stage study tests an experimental drug, NNC4004-0002, in 60 adults with high uric acid levels but no symptoms. The main goal is to check safety and how the body handles a single injection. Participants receive either the drug or a placebo (saline) by chance. The study …

This study compares the experimental drug CagriSema (cagrilintide and semaglutide) to a calorie-reduced diet in 80 adults with obesity. It measures how each approach changes the body's energy use, like sleeping metabolic rate. The study lasts about 1.5 years, and all participants…

This early-stage study tests a new medicine called NNC0581-0001 in 48 adults with fatty liver and possible liver inflammation. Participants receive either the drug or a placebo as a monthly injection for 3 months. The main goal is to check safety and how the drug moves through th…

This study tests a new weekly injection (NNC0519-0130) in 465 adults with chronic kidney disease, with or without type 2 diabetes, who are also overweight or obese. The goal is to see if the drug safely improves kidney function compared to an existing medicine (semaglutide) or a …

This early-stage study tests how a new medicine, NNC0487-0111, affects insulin sensitivity and pancreas function in adults with type 2 diabetes. About 80 participants will receive either the study drug or a placebo. The goal is to see if the drug can help the body use insulin bet…

This study tests an experimental drug, NNC6019-0001, to see if it can lower the risk of heart-related death and hospital stays in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that stiffens the heart. About 1,280 adults will be randomly assigned to receive…

This study tests a new drug called etavopivat to see if it can lower the number of painful sickle cell crises (VOCs) in people aged 12 and older with sickle cell disease. About 408 participants will receive either the drug or a placebo by chance. The trial lasts about 2 years and…

This study looks at how safe the medicine eptacog alfa is for women in India who have severe bleeding after giving birth. About 64 women will receive one or two doses of the drug and be monitored for side effects like blood clots or allergic reactions over about a month. The goal…

This program provides free daily injections of concizumab to people with congenital haemophilia who have no other good treatment options. Participants will be monitored for safety and effectiveness over several years with regular clinic visits and blood tests. The program continu…

This study tests a new once-weekly injection called NNC0487-0111 in 630 adults with overweight or obesity and type 2 diabetes. Participants receive either the active drug or a placebo to see if it safely helps with weight loss and blood sugar control. The trial is currently recru…

This study tests whether a new medicine called UBT251 is safe and helps people with overweight or obesity lose weight. About 333 adults will receive either UBT251 or a placebo (dummy treatment) by chance. The main goals are to check for side effects and measure weight change over…

This study tests whether a new medicine called NNC0487-0111, given as a weekly injection, is safe and effective for weight loss in adults with obesity. About 600 participants will receive either the active drug or a placebo (dummy injection) for comparison. The main goal is to me…

This study compares a new insulin that is injected once a week (insulin icodec) to a standard daily insulin (insulin glargine) in about 877 adults with type 1 diabetes. The goal is to see if the weekly insulin controls blood sugar just as well as the daily one. Participants will …

This study tests whether two new drugs, CagriSema and cagrilintide, can help children and adolescents with overweight or obesity lose weight. About 460 participants will receive either the study drugs, an existing drug (semaglutide), or a placebo. The main study lasts about 1.5 y…

This early-stage study tests a new weekly injection called NNC0497-0040 in up to 146 people. It includes healthy volunteers, people who are overweight or obese, and those with type 1 diabetes who are also overweight or obese. The main goal is to check if the drug is safe and tole…

This early-stage study tests a new medicine, NNC6989-0001, for safety and tolerability in 96 healthy adults who are overweight or have obesity. Participants receive either the drug or a placebo by chance. The goal is to check for side effects and how the drug moves through the bo…

This study tests a once-weekly injection called NNC0487-0111 in 400 adults who are overweight or have obesity and also have knee osteoarthritis. The goal is to see if the drug helps with weight loss and reduces knee pain and stiffness compared to a placebo. Participants will rece…

This study tests whether ziltivekimab, an experimental drug, can improve symptoms and daily function in people with heart failure who also have signs of inflammation. About 680 participants will receive either the drug or a placebo by chance. The main goal is to see if the drug h…

This early-stage study tests a new medicine (NNC9733-0001) to see if it is safe and can lower high blood sugar in people with type 2 diabetes. About 72 healthy volunteers and people with diabetes will receive either the study drug or a placebo as a single injection. The trial las…

This study looks at whether combining two experimental drugs (cagrilintide and NNC0480-0389) causes fewer stomach side effects like nausea and vomiting than taking cagrilintide alone. About 100 women with overweight or obesity will receive both combinations at different times. Th…

This study tests a medicine called cagrilintide to see how it affects hunger and how much people eat. About 120 adults with overweight or obesity will receive either the study drug or a placebo for around 30 weeks. The goal is to measure changes in total calorie intake from meals…

This study tests a new once-weekly injection (NNC0487-0111) in 400 adults with overweight or obesity and knee osteoarthritis. The goal is to see if it helps with weight loss and reduces knee pain compared to a placebo. Participants are randomly assigned to receive either the acti…

This study tests a new drug called NNC0537-1482 in 36 adults with heart failure to see if it is safe and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo (dummy pill) for up to 64 days. The goal is to check for side effects and…

This early-stage study tests whether a once-weekly injection called NNC0487-0111 can lower how much people with obesity eat and reduce their appetite. About 120 adults will receive either the drug or a placebo for several months. The goal is to see if the treatment changes energy…

This study looks at medical records of 400 adults aged 40-70 in Southeast Asia who were recently diagnosed with type 2 diabetes. The goal is to understand their heart disease risk factors, like blood pressure and cholesterol, at the time of diagnosis and during the first year. No…

This study looks at how long you need to fast and whether temporarily stopping GLP-1 medications (like liraglutide or semaglutide) affects how much food stays in your stomach. Researchers will measure stomach emptying after a high-fat meal in 75 adults with obesity who already ta…

This study will look at medical records of about 900 male children and adults with hemophilia A in Iraq to see how the clotting medicine turoctocog alfa is used in daily care. The goal is to understand bleeding rates and treatment patterns, but the study does not change or interf…

This study follows up on people who already received the experimental obesity drug INV-347 in an earlier study. No new medication is given. Researchers will track side effects and measure how long the drug stays in the body. The goal is to better understand the drug's long-term s…

This study looks at how a new medicine for overweight or obesity (NNC0662-0419) affects the way the body processes birth control pills and a common painkiller. It involves 45 women who cannot become pregnant and are generally healthy aside from being overweight or obese. The goal…

This early-stage study is for people with a heart condition called ATTR-CM, where abnormal protein builds up in the heart. Researchers are testing a new medicine, coramitug, that may help remove these protein clumps. The study uses special PET/CT scans to see how the drug travels…

This study tests a new medicine called Inno8 for hemophilia A. Researchers want to see how eating and drinking before and after taking the pill changes how much medicine gets into the blood. 80 healthy men aged 18-45 will take one dose after fasting, then wait different times bef…